The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2012Phosphorylated Alpha-synuclein Species as Biomarkers for Diagnosis and Progression in Parkinson’s disease
Objective/Rationale:
Diagnosis of Parkinson’s disease would be facilitated by the discovery of objective biomarkers for identifying it at early stages and differentiating it from other related... -
MJFF Research Grant, 2012The Role of Alpha-synuclein in the Pathogenesis of Parkinson’s Disease in a Pre-clinical Model
Objective/Rationale:
Preliminary data from our laboratory demonstrated that the protein alpha synuclein (a-syn) might play a major role in an inherited autosomal recessive pre-clinical model for... -
MJFF Research Grant, 2012Using External Research Experts to Mine the 23andMe Parkinson’s Dataset
Objective/Rationale:
Currently at 23andMe we have whole-genome genotype data for 5,449 Parkinson’s disease (PD) patients and 110,853 healthy subjects. This is by far the largest cohort of case-control... -
Therapeutics Development Initiative, 2012Targeting System-xc for the Treatment of Parkinson's Disease
Objective/Rationale:
Parkinson’s disease is characterized by the progressive loss of dopamine neurons in brain regions responsible for motor coordination and activity – disturbances of which are... -
MJFF Research Grant, 2012Pharmacological Targeting of the 5-HT1, A2A and NMDA Receptors: An Integrative Approach to Dyskinesia
Objective/Rationale:
The glutamate, serotonin and adenosine systems are interesting targets for pharmacological therapies in Parkinson´s disease. However, interventions addressed at single systems... -
Target Validation, 2012Validation of ATP13a2 / PARK9 as a Target to Reduce Neurodegeneration Induced by Alpha-Synuclein
Objective/Rationale:
Alpha-synuclein plays a prominent role in Parkinson’s disease and identifying valid targets to ameliorate the neurodegenerative effects of alpha-synuclein is a major therapeutic...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.